Our Sole Focus:
Human Therapeutic Antibody Discovery
We understand how to position your discovery program for success while navigating through potential pitfalls, because we have years of experience in generation of therapeutic-quality antibodies from rodents, both wild-type and transgenic.
We work with companies large and small, ranging from companies operating virtually to established companies wanting to enhance their existing capabilities.
Our team of experts will become your team of experts, creating a tailored therapeutic discovery project based on the proven AlivaMab Mouse platform.
Justin is CEO of AlivaMab Discovery Services. He has served in executive roles in both biotechnology and contract research organizations for almost 15 years. His most recent position was the Senior Vice President of Strategy and Business Development in the Eurofins Drug Discovery Division and General Manager of Eurofins DiscoverX. Here, his scope included defining strategies across eight Eurofins owned companies, global sales, integration activities, client services teams, business improvement initiatives, innovation, and M&A. In addition to his divisional role, Justin had full P&L responsibilities for the largest drug discovery company in the Eurofins portfolio, Eurofins DiscoverX.
Prior to Eurofins, Justin led the drug discovery service divisions of DiscoverX including three sites in California and one in the United Kingdom. These sites included DiscoverX’s LeadHunter Drug Discovery Services and the acquisitions of Ambit Bioscience’s KINOMEscan platform in 2010 and BioSeek platform in 2012. In 2017, DiscoverX was acquired by Eurofins. Justin received his M.S. and M.B.A. from University of Delaware, conducted research at Princeton University, and received his B.Sc. from Penn State University.
John “Lippy” Lippincott, Ph.D.
Vice President of Research
Lippy is Vice President of Research at AlivaMab Discovery Services. He has over two decades of experience in the generation and characterization of antibodies from in vivo systems.
Prior to joining AlivaMab Discovery Services, Lippy established and led the hybridoma group at Pfizer’s San Diego site, where he was project leader for internal and co-development therapeutic discovery projects. At Igenica, he led the successful importation of a novel in vivo discovery platform and created a high-throughput system for hybridoma generation and screening, and led other processes required for identifying lead therapeutic candidates. Serving in the role of Vice President, Antibody Discovery at LakePharma, Lippy built and led the team responsible for providing antibody discovery services to clients. Lippy received his Ph.D. from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.
Board of Directors
Larry Green, Ph.D.
Chairman of Board
Larry Green, Ph.D., is Chairman of the Board of AlivaMab Discovery Services and co-inventor of the AlivaMab® Mouse. He also serves as Chief Executive Officer of Ablexis, LLC. Larry has a quarter century of experience in designing, building and using antibody drug discovery platforms, which has resulted in seven approved antibody drugs and multiple others in clinical trials. He is an inventor on over 60 US patents covering therapeutic product candidates and immunoglobulin transgenic mice, including the XenoMouse® platform (Abgenix/Amgen) and the AlivaMab Mouse platform (Ablexis), plus dozens of issued patents in other geographies. He has served as a founder of three companies, Abgenix, Inc. (founded 1996, acquired by Amgen, Inc. in 2006), Ablexis, LLC (founded 2009, acquired by Deerfield Management Company in 2018), and AlivaMab Discovery Services, LLC (founded 2018). He holds a Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and a B.Sc. with honors in Chemistry from the University of Kentucky.
Robert Jackson, M.D.
Robert Jackson, M.D., is a Partner and Chief Science Officer at Deerfield and joined the Firm in 2001. Prior to Deerfield, Dr. Jackson was a healthcare analyst at Janus Capital. Previously, he founded and managed a group ophthalmology practice. Dr. Jackson holds an undergraduate degree from Rollins College, M.D. from West Virginia University and M.B.A. with distinction from the Wharton School at the University of Pennsylvania. He was a Cleveland Fellow at Case Western Reserve University, spent a year at the Royal Melbourne Hospital in Australia, completed his ophthalmology residency at Case Western Reserve University and was Chief Resident in his final year.
Cameron Wheeler, Ph.D.
Cameron Wheeler, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals, Inc. and a Senior Associate at Third Rock Ventures, LLC. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.